Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

NCT06236061 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

718

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension

Interventions

DRUG: LCZ
DRUG: LCZ/AML 200 mg/2.5 mg
DRUG: LCZ/AML 200 mg/5 mg
DRUG: LCZ/AML 200 mg/10 mg
OTHER: Placebo

Sponsor

Novartis Pharmaceuticals